Oruka Therapeutics (NASDAQ:ORKA) Given New $75.00 Price Target at UBS Group

Oruka Therapeutics (NASDAQ:ORKA) had its price target boosted by UBS Group from $50.00 to $75.00 in a research report released on Monday,Benzinga reports. UBS Group currently has a buy rating on the stock.

ORKA has been the topic of several other reports. Leerink Partners lifted their price target on shares of Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Stifel Nicolaus boosted their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, BTIG Research restated a “buy” rating and set a $73.00 target price on shares of Oruka Therapeutics in a report on Friday, March 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.10.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $56.37 on Monday. The firm’s 50 day simple moving average is $37.40 and its 200 day simple moving average is $31.02. The company has a market capitalization of $2.79 billion, a P/E ratio of -30.31 and a beta of -0.54. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $58.99.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. On average, equities analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. The trade was a 18.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 23,765 shares of company stock valued at $849,575. 24.69% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Oruka Therapeutics during the 4th quarter valued at about $67,000. Seven Fleet Capital Management LP bought a new position in Oruka Therapeutics in the 4th quarter worth approximately $159,000. Invesco Ltd. boosted its stake in Oruka Therapeutics by 777.1% in the 4th quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock worth $4,338,000 after purchasing an additional 126,803 shares during the period. Virtus Investment Advisers LLC purchased a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $267,000. Finally, RTW Investments LP raised its holdings in shares of Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after acquiring an additional 112,499 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.